Bristol-Myers Squibb and Meso Scale Discovery Enter Agreement to Develop Diagnostic Assays for Alzheimer’s Disease

Category:

Wednesday, March 28, 2012 8:00 am EDT

Dateline:

PRINCETON, N.J. & GAITHERSBURG, Md.

Public Company Information:

NYSE:
BMY
"Bristol-Myers Squibb is a leader in the field of Alzheimer’s disease research and brings a clinical development perspective that pairs well with our experience in developing high-quality assays."

PRINCETON, N.J. & GAITHERSBURG, Md.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) and Meso Scale Discovery today announced they have entered an agreement to develop diagnostic assays that will measure cerebrospinal fluid biomarkers for use in Alzheimer’s disease research.

Under the terms of the agreement, the companies will develop these assays based on the Meso Scale Discovery® MULTI-ARRAY technology platform. Meso Scale Discovery will commercialize the assays for Alzheimer’s disease research and drug development, and plans to release the assays in the second quarter of 2012. Terms of the agreement were not disclosed.

“The collaboration with Meso Scale Discovery demonstrates Bristol-Myers Squibb’s commitment to advancing the science of Alzheimer’s disease research,” said Jane Tiller, vice president, Global Clinical Research, Bristol-Myers Squibb. “These assays could provide the Alzheimer’s disease research community with an important tool to help advance understanding of this complex and devastating disease and may lead to advances in the diagnosis and treatment of Alzheimer’s disease.”

“This partnership fits perfectly into our mission of developing novel biomarkers tests for use in research and diagnostics,” said Jacob Wohlstadter, President and CEO of Meso Scale Discovery. “Bristol-Myers Squibb is a leader in the field of Alzheimer’s disease research and brings a clinical development perspective that pairs well with our experience in developing high-quality assays.”

About Alzheimer's disease

Alzheimer's disease is a progressive brain disease that impairs memory, interferes with thinking and ultimately destroys the ability of an individual to carry out simple tasks. The disease is a continuum, with damage to the brain starting long before the onset of dementia. Alzheimer's affects 24 million people worldwide and the prevalence is projected to significantly increase over the coming decades due to the aging population. While there are medicines available to help treat the symptoms of Alzheimer's disease, there remains a significant unmet medical need for therapies that slow or prevent the progression of underlying disease.

About Bristol-Myers Squibb

Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol-Myers Squibb, visit www.bms.com, or follow us on Twitter at http://twitter.com/bmsnews.

About Meso Scale Discovery

Meso Scale Discovery, a division of Meso Scale Diagnostics, LLC (MSD®) develops and markets solutions for multiplex biological assays, including assays for biomarkers, cytokines and phosphoproteins. MSD's platform is based on MULTI-ARRAY® technology, a proprietary combination of patterned arrays and electrochemiluminescence detection, enabling large numbers of measurements with exceptional sensitivity, wide dynamic range and convenience. For more information about MSD visit www.mesoscale.com®.

Contact:

Bristol-Myers Squibb
Media:
Jennifer Fron Mauer, +1-609-252-6579
jennifer.mauer@bms.com
or
Investors:
John Elicker, +1-609-252-4611
john.elicker@bms.com
or
Meso Scale Discovery
Media and Investors:
Deborah Wohlstadter, +1-240-631-2522
pr@meso-scale.com

Search Press Releases

Reset



Subscribe to E-Mail Alerts

Business Wire NewsHQ℠